Personalis, Inc. (NASDAQ:PSNL) Stock Has Consensus Price Target of $14.54

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned an average recommendation of “Hold” from the eleven analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $14.54.

PSNL has been the subject of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Craig Hallum lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target on the stock. in a report on Monday, August 24th. UBS Group downgraded Personalis from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 6th. Zacks Research raised shares of Personalis from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Finally, BTIG Research cut shares of Personalis from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 6th.

Personalis Stock Performance

PSNL opened at $15.88 on Thursday. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -14.57 and a beta of 2.32. The company has a fifty day moving average of $16.27 and a 200 day moving average of $11.17. Personalis has a fifty-two week low of $4.95 and a fifty-two week high of $18.89.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%.

Insider Activity

In related news, CEO Christopher Hall sold 7,459 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $120,984.98. Following the sale, the chief executive officer directly owned 228,527 shares of the company’s stock, valued at $3,706,707.94. This represents a 3.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $33,542.96. Following the completion of the sale, the senior vice president directly owned 90,257 shares of the company’s stock, valued at approximately $1,463,968.54. The trade was a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 16,456 shares of company stock valued at $266,916. 4.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Personalis

Hedge funds have recently added to or reduced their stakes in the stock. Penobscot Investment Management Company Inc. purchased a new stake in Personalis during the third quarter worth $182,000. Fortitude Family Office LLC purchased a new stake in shares of Personalis during the 3rd quarter worth $164,000. Tidal Investments LLC purchased a new stake in shares of Personalis during the 2nd quarter worth $1,146,000. WINTON GROUP Ltd bought a new stake in Personalis during the second quarter valued at about $496,000. Finally, Engineers Gate Manager LP bought a new stake in Personalis during the second quarter valued at about $1,552,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.